Analysts Say Buy These Stocks: Shire plc (NASDAQ:SHPG), Tesco Corporation (NASDAQ:TESO), Core-Mark Holding Company, Inc. (NASDAQ:CORE), Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP)

Wall Street analysts are maintaining Buy rating on Shire plc (NASDAQ:SHPG) company shares.  The one year target on the name currently stands at $233.38.  The stock recently touched $167.88 and has moved in the range of $165.95 - 168.38 during the current session.  Based on a recent bid this places the stock +13.74% away from the 52-week floor of $147.60 and -37.97% away from the 52-week ceiling of $270.63.

When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary.  Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth.  Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year.  Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.

Tesco Corporation (NASDAQ:TESO) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $9.75 on the stock. The stock is currently trading +19.56% away from its 200-day moving average of $7.40. Based on a recent trade, shares of Tesco Corporation are -33.36% away from the 52-week high of $13.28 and +72.51% away from the 52-week low of $5.13.

Analysts are estimating that the company will report earnings of $-1.24 for the current year and $-0.33 for next quarter. The stock closed the most recent trading session at $9.08.

Shares of Core-Mark Holding Company, Inc. (NASDAQ:CORE) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $93.20 price target and Buy rating according to the covering analysts.  During today’s session the stock hit $79.56 or -1.57% from the previous close, while moving in the range of $78.91 - 81.20.

Shares of Adaptimmune Therapeutics PLC - ADR (NASDAQ:ADAP) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $18.80 price target according to the covering analysts.  During today’s session the stock hit $7.82 or +6.27% from the previous close, while moving in the range of $7.87 - 8.45.  This puts the stock -61.47% away from the 52-week high of $21.57 and +34.25% away from the 52-week low of $6.19.

Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm.  The consensus rating simply provides an average of those recommendations.  It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Add Comment